THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL

胰高血糖素抑制剂普兰林肽和艾塞那肽对餐后的影响

• 批准号: 8166727
• 负责人: LUISA M RODRIGUEZ
• 金额: $ 0.46万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166727
• 关键词: Adult; Agonist; Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Dose; Funding; GLP-I receptor; Glucagon; Glucose; Grant; Hyperglycemia; Incidence; Institution; Insulin; Laboratories; Non-Insulin-Dependent Diabetes Mellitus; Patients; Population; Pramlintide; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; analog; exenatide; glucagon-like peptide 1; glycemic control; hyperglucagonemia; improved; islet amyloid polypeptide; macrovascular disease; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The use of glucagon suppressors¿?? pramlintide and exenatide is well established in adult patients with T2DM, but there is a lack of information regarding an effective glucose lowering effect in pediatric T2DM. Previous studies from our laboratory showed that there is unabated early postprandial hyperglucagonemia in children with T2DM contributing to the marked postprandial hyperglycemia. There is insulin, amylin and GLP-1 deficiency in children with T2DM requiring insulin therapy. Both amylin and GLP-1 are potent endogenous glucagon suppressors. The glucose and glucagon lowering effect of the amylin analog pramlintide and the GLP-1 receptor agonist exenatide will be tested in insulin requiring children with T2DM. The lowest adult recommended doses would be used. With an increasing incidence of T2DM in the pediatric population, it is incumbent upon us to research new therapies in an effort to improve glycemic control and prevent the long-term micro and macrovascular complications associated with diabetes. We hypothesize that preprandial administration of a glucagon suppressor will decrease postprandial hyperglycemia and hyperglucagonemia in insulin treated children with T2DM. The objective is to determine the effect of the glucagon suppressors pramlintide and exenatide independently administered on: a) Glucose excursions b) Glucagon concentrations.

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 使用胰高血糖素的建议？在T2DM的成年患者中，pramlintide和Actenatide已很好地确定，但是缺乏有关小儿T2DM有效葡萄糖降低作用的信息。我们实验室的先前研究表明，T2DM儿童的餐后早期高葡萄糖血症有效，导致明显的餐后高血糖。需要胰岛素治疗的T2DM儿童中有胰岛素，淀粉纤维和GLP-1缺乏症。淀粉蛋白和GLP-1都是潜在的内源性胰高血糖素补充剂。将在需要T2DM儿童的胰岛素中测试淀粉蛋白类似物现象和GLP-1受体激动剂的葡萄糖和胰高血糖素降低作用。最低的成人建议剂量将使用。随着小儿人群中T2DM的发生率的增加，我们有责任研究新疗法，以改善血糖控制并防止长期的微血管并发症与糖尿病相关。 我们假设，胰高血糖素抑制剂的前施用将减少胰岛素治疗儿童T2DM的餐后高血糖和高葡萄糖症。目的是确定胰高血糖素抑制剂的效应，并独立地施用： a）葡萄糖游览 b）胰高血糖素浓度。